Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IntraBiotics Protegrin IB-367 Rinse

Executive Summary

Collaborative development and marketing agreement with Pharmacia & Upjohn is terminated and global rights to market the topical antimicrobial rinse returned to IntraBiotics, the Mountain View, Calif.-based company announced Aug. 10. Under an October 1997 agreement, the companies were jointly developing Protegrin IB-367 rinse for the treatment and prevention of oral mucositis in the U.S; P&U had exclusive rights in all other markets. P&U's decision is related to Protegrin's potential market size relative to P&U's product pipeline, IntraBiotics said. The product has completed Phase II trials, and Phase III studies are expected to begin in the first half of 2000
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS034680

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel